Rabbit Recombinant Monoclonal Androgen receptor variant 5,6,7es antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
WB | IHC-P | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes It is suggested to use the low dilution in natural material as 1/10,000 is based on over-expressed lysate testing. Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes Perform heat-mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. |
AR, AR-FL, AR-V567es, AR-Vs, Androgen receptor splice variants
Rabbit Recombinant Monoclonal Androgen receptor variant 5,6,7es antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
This ARv567es antibody (clone EPR15657) is a rabbit monoclonal antibody against Human Androgen receptor variant 5,6,7es (aa 700 to the C-terminus). This antibody does not react with AR-FL.
ab251320 is the carrier-free version of Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827.
Anti-ARv567es RabMAb product (Clone EPR15657) has been highlighted in the following poster: Identification of ARv567es expression profile in the prostate cancer clinical samples with a newly developed antibody.
For ARv7 specific RabMAb antibody - see Anti-Androgen Receptor (AR-V7 specific) antibody [EPR15656] ab198394.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
The androgen receptor variant 567es often shortened to AR-V567es is a splice variant of the androgen receptor (AR) integral in regulating gene expression in response to androgens. This receptor plays a role in the signal transduction of androgens like testosterone and dihydrotestosterone. The molecular weight of this variant is around 110 kDa. AR-V567es lacks the ligand-binding domain present in the full-length androgen receptor which enables its activity even in the absence of natural androgens. This variant expresses mainly in prostate tissue and some other tissues sensitive to androgens.
The androgen receptor variant 567es acts as a transcription factor influencing a range of cellular processes including proliferation and survival. It remains involved in the androgen receptor signaling axis playing a vital role even when standard androgen receptor pathways are downregulated or inhibited. Although it functions independently AR-V567es may interact with other coregulators to influence gene regulation. It does not form part of a larger protein complex but works independently to modulate specific androgen-responsive genes maintaining cellular growth and differentiation signals.
This androgen receptor variant engages in the androgen receptor signaling pathway which remains fundamental for the development and function of male characteristics. It is also critical in maintaining the proliferation of prostate cells. Related proteins in these pathways include the full-length androgen receptor and the steroid receptor coactivators which help modulate gene expression. The absence of a traditional ligand-binding domain in AR-V567es confers distinct roles compared to its ligand-dependent counterparts.
Androgen receptor variant 567es is notably linked to prostate cancer where it contributes to the progression of castration-resistant prostate cancer (CRPC). This variant's ability to be active without typical androgen binding enables continued cancer cell survival and proliferation despite androgen-deprivation therapies. Additionally the presence of AR-V567es connects with alterations in the androgen receptor network where it interacts with other variant receptors to drive resistance to conventional anti-androgen treatments. This makes it a significant target for developing new therapeutic strategies against CRPC.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This data was developed using Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling Androgen receptor variant 5,6,7es with Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution. Cytoplasmic and nuclear staining on Human prostate cancer tissue is observed. Counter stained with Hematoxylin. Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
This data was developed using Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
All lanes: Western blot - Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] (Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827) at 1/1000 dilution
Lane 1: Human fetal liver tissue lysate at 10 µg
Lane 2: PC-3 (Human prostate adenocarcinoma cell line) whole cell lysate at 10 µg
Lane 3: LNCaP (Human prostate cancer cell line) whole cell lysate at 10 µg
Lane 4: T-47D (Human ductal breast epithelial tumor cell line) whole cell lysate at 10 µg
Lane 5: Human prostate tissue lysate at 10 µg
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 77 kDa
Exposure time: 3min
This data was developed using Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827, the same antibody clone in a different buffer formulation.
Blocking and dilution buffer: 5% NFDM/TBST.
Full length ARV567es M12 overexpress lysate containing aa1-739 with 3x DDDDK-tag was supplied by Stephen R. Plymate, M.D. Professor, Department of Medicine, University of Washington, Seattle, WA.
Liu G. et al. 2013. AR variant ARv567es induces carcinogenesis in a novel transgenic mouse model of prostate cancer. Neoplasia 15, 1009-1017.
Cao B. et al. 2014. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget 5, 1646-1656.
All lanes: Western blot - Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] (Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827) at 1/10000 dilution
All lanes: M12-3FARV567es
All lanes: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 77 kDa
Observed band size: 100 kDa
Exposure time: 3min
This data was developed using Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling Androgen receptor variant 5,6,7es with Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution. Cytoplasmic and nuclear staining on Human prostate cancer tissue is observed. Counter stained with Hematoxylin. Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
This data was developed using Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of paraffin-embedded Human prostate cancer tissue labeling Androgen receptor variant 5,6,7es with Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution. Negative on Human prostate cancer. Counter stained with Hematoxylin. Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
This data was developed using Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827, the same antibody clone in a different buffer formulation.Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling Androgen receptor variant 5,6,7es with Anti-Androgen receptor variant 5,6,7es antibody [EPR15657] ab200827 at 1/500 dilution, followed by Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) secondary antibody at 1/500 dilution. Negative on Human liver tissue. Counter stained with Hematoxylin. Secondary antibody only control: Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/500 dilution. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com